FY2027 Earnings Forecast for BPMC Issued By Leerink Partnrs

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Research analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Blueprint Medicines in a research report issued on Tuesday, January 14th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will earn $4.98 per share for the year. The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.68) per share.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period in the prior year, the company earned ($2.20) EPS. The company's quarterly revenue was up 126.5% compared to the same quarter last year.

A number of other equities analysts have also commented on the stock. HC Wainwright reissued a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. Needham & Company LLC reissued a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Monday. UBS Group began coverage on Blueprint Medicines in a research note on Thursday, October 24th. They set a "neutral" rating and a $88.00 price target for the company. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a report on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price objective for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a report on Wednesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $122.72.

Blueprint Medicines Price Performance

Shares of BPMC stock traded down $0.81 during trading on Thursday, hitting $104.08. The company had a trading volume of 477,611 shares, compared to its average volume of 948,690. Blueprint Medicines has a 52 week low of $72.24 and a 52 week high of $121.90. The stock has a market capitalization of $6.61 billion, a price-to-earnings ratio of -49.33 and a beta of 0.61. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock's 50-day moving average is $93.85 and its two-hundred day moving average is $95.36.

Insider Activity at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the sale, the director now owns 157,557 shares of the company's stock, valued at approximately $16,114,929.96. The trade was a 3.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40. Following the completion of the transaction, the chief operating officer now directly owns 71,657 shares of the company's stock, valued at approximately $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,970 shares of company stock worth $2,914,246 in the last 90 days. Company insiders own 4.21% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BPMC. Empirical Asset Management LLC purchased a new position in shares of Blueprint Medicines in the 4th quarter valued at approximately $2,348,000. Exome Asset Management LLC purchased a new position in Blueprint Medicines during the third quarter valued at $3,395,000. Franklin Resources Inc. lifted its position in Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after buying an additional 265 shares during the period. Synovus Financial Corp grew its position in shares of Blueprint Medicines by 4.0% in the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company's stock worth $2,224,000 after buying an additional 922 shares during the period. Finally, Sanctuary Advisors LLC bought a new position in shares of Blueprint Medicines in the 3rd quarter worth about $202,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.